Jefferies Starts Medpace (MEDP) at Hold
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies initiates coverage on Medpace (NASDAQ: MEDP) with a Hold rating and a price target of $32.50.
Analyst David Windley commented, "We initiate on MEDP with a $32.50 PT and Hold rating on valuation (+33.5% since pricing). MEDP competes in the phase I-IV CRO space, wins mandates with its therapeutic expertise and responsiveness, and delivers very high margin via its prescriptive operating model. We have credited MEDP's superior cash flow in our PT; however, quarterly volatility in operating metrics and the current biotech funding environment keep us from being more aggressive on valuation."
Shares of Medpace closed at $30.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
- AK Steel (AKS) PT, Estimates Raised at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!